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Abstract
Background: Drug-induced eosinophilic myocarditis is a life-threatening and frequently overlooked condition. The
prevalence of myocarditis in clozapine-treated patients may be as high as 3 %. An association between olanzapine
and myocarditis has not previously been described, but given the chemical similarity between olanzapine and
clozapine, we hypothesized the existence of such an association. We searched the spontaneous adverse drug
reports database of the Danish Health and Medicines Authority for olanzapine and myocarditis in the period from
October 21, 1996 to – June 03, 2015. We identified two fatal cases of eosinophilic myocarditis associated with the
use of olanzapine.
Case presentation: Case 1 was a 39-year-old Caucasian man with known substance abuse and schizophrenia. He
was found dead in his home. Olanzapine was prescribed at day -54, and dose at time of death was 40 mg/day.
Post-mortem toxicological examination demonstrated presence of olanzapine, morphine, venlafaxine and oxazepam.
Syringes indicating substance abuse were found in his home.
Case 2 was a 36-year-old Caucasian man diagnosed with schizophrenia was found dead unexpectedly. There was no
history of substance abuse. Current treatment was olanzapine 20 mg/day +5 mg as PRN (prescribed for almost 4 years),
aripiprazole 30 mg/day (prescribed for 6 months) and mirtazapine 30 mg/day (prescribed for 6 months).
Both cases of eosinophilic myocarditis were confirmed by autopsy findings and both patients received olanzapine in
doses exceeding the recommendations.
Conclusion: Olanzapine may have contributed to and/or worsened the two reported fatal cases of myocarditis.
Additional studies are required to establish a causal link between olanzapine and eosinophilic myocarditis.
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Background
Myocarditis, defined as an inflammatory condition of the
myocardium, may lead to myocardial fibrosis, arrhythmias
and sudden cardiac death. Etiological factors for myocar-
ditis include i) infections (with viruses, bacteria, fungi,
protozoa or parasites), ii) autoimmune mechanisms, and
iii) substances/drugs (toxic effects or hypersensitivity reac-
tions). The diagnosis is based on endomyocardial biopsies
where histological examination reveals inflammatory
infiltrates and myocardial necrosis in the same section
(the so-called Dallas criteria). Additional analyses such as
immune-histochemistry, molecular techniques (e.g. poly-
merase chain reaction) and myocardial imaging may also
be required [1]. Eosinophilic myocarditis (EM), which is a
rare form of myocarditis constituting 0.5 % of all myocar-
ditis autopsy cases [2], is characterized by abundant eosin-
ophils in the inflammatory infiltrate. These eosinophils
release toxic factors that induce apoptosis and necrosis of
myocytes. Often, EM is not recognized in living patients,
and the diagnosis is therefore given at the time of autopsy
[3]. EM is associated with systemic autoimmune disorders
and hypereosinophilic syndromes. Importantly, drug-
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induced hypersensitivity reactions can also cause EM. The
most common agents in this regard are clozapine, antibi-
otics and antiphlogistics [4, 5]. A recent study from
Australia has suggested that clozapine-induced myocardi-
tis is a highly overlooked adverse effect with an actual
prevalence as high as 3 % [6].
In addition to clozapine, there are anecdotal reports sug-
gesting a possible association between other psychotropic
drugs and the development of EM. These include the tri-
cyclic antidepressants amitriptyline [7] and imipramine [8],
the first generation antipsychotic (FGA) perphenazine [9],
and more recently the second generation antipsychotic
(SGA) quetiapine [10]. Furthermore, animal studies have
revealed that different antipsychotics to a various extent in-
duce cardiac alterations (ventricular hypertrophy, myocar-
dial necrosis and fibrosis) comparable to what can be seen
in myocarditis [11]. Altogether, this suggests that additional
antipsychotics may cause EM. As clozapine-induced myo-
carditis may be overlooked, we proposed that this might
also be the case for olanzapine, which is chemically related
to clozapine as shown in Fig. 1.
Method
We searched the spontaneous adverse drug reports data-
base of the Danish Health and Medicines Authority for
olanzapine and myocarditis in the period from October
21, 1996 to – June 03,.2015. In total we identified 405
adverse drug reaction (ADR) reports involving olanzapine,
including, two fatal cases of EM associated with the use of
olanzapine. No non-fatal cases of olanzapine associated
myocarditis were found. Case 2 has been published else-
where with the focus on sudden cardiac death and associ-
ation to aripiprazole [12]. Presentation of cases was based
on ADR reports with no direct access to patient records.
Case presentation
Case 1
Thirty-nine-year-old man with known substance abuse
and schizophrenia was found dead (day 0). Syringes with
traces of morphine and tetrahydrocannabinol were found
close to the body. There was no reports on previous
physical disease. Olanzapine was prescribed at day -54,
and dose at time of death was 40 mg/day. At day -48 preg-
abalin was prescribed for anxiety. Venlafaxine was pre-
scribed for major depression; dosage was not specified.
Additionally, oxazepam was prescribed for anxiety and
used for various dosages for up to 5 years. Post-mortem
toxicological examination demonstrated presence of olan-
zapine (0.15 mg/kg), morphine (0.12 mg/kg), venlafaxine
(0.22 mg/kg), oxazepam (0.07 mg/kg), diazepam (0.31 mg/
kg) and pregabalin (3.1 mg/kg). Plasma levels were not re-
ported but described as within the therapeutic range. At
autopsy, cause of death was considered to be myocarditis,
which probably had led to a lethal arrhythmia. Upon
histological examination of cardiac tissue, there were
several sections with myocardial necrosis and abundant
eosinophilic granulocytes, indicating EM.
Case 2
Thirty-six-year-old man diagnosed with schizophrenia
was found dead (day 0). The death was unexpected as the
patient had no substance abuse, suicidal ideation or
known physical disease. Current treatment was olanzapine
20 mg/day +5 mg as PRN (prescribed for almost 4 years),
aripiprazole 30 mg/day (prescribed for 6 months) and
mirtazapine 30 mg/day (prescribed for 6 months). Post-
mortem toxicological analyses revealed aripiprazole
0.7 mg/kg, mirtazapine 0.07 mg/kg and olanzapine
0.10 mg/kg. Autopsy demonstrated fibrous tissue in the
inferior part of the cardiac septum. Histological examin-
ation of the fibrous area in the septum as well as from
macroscopically normal structures in the heart, showed
presence of interstitial fibrosis and myocyte necrosis.
These lesions were of different age, and the more recent
ones contained inflammatory cells with a dominance of
eosinophilic granulocytes. Certain cause of death could
not be established, but cardiac arrhythmia after EM was
suspected.
Discussion
Olanzapine, which has a chemical structure relatively
similar to that of clozapine, has so far not been linked to
myocarditis. Here, we report two cases where post mor-
tem analyses indicated death due to EM. For both cases,
olanzapine may have contributed to and/or worsened
the disease process.
In general, EM is a rare disease constituting only 0.5 %
of all cases of myocarditis. Since the symptoms may be
vague/nonspecific or self-limiting and the clinicians tend
to miss the diagnosis, the condition is often first identified
at the time of autopsy. This was also the case for our two
patients and may also explain why no cases of non-fatal
EM were found in the database.
Notably, drug-induced hypersensitivity reactions and/
or toxic effects are important causes of EM. Given the
Fig. 1 Chemical structure of clozapine and olanzapine
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paucity of autoimmune manifestations, hypereosinofilic
syndromes and parasitic infections in our two patients,
it is most likely that they died from drug-induced EM.
Toxicological analyses of blood from case 1 indicated
presence of olanzapine, venlafaxine, morphine, pregabalin,
diazepam and oxazepam, none of which in abnormal levels.
Neither of these have previously been associated with EM.
For the following three reasons, we favor a model where
EM was induced by olanzapine in case 1. First, olanzapine
is structurally related to clozapine, which is well-known to
cause EM. Furthermore, other psychotropics such as the
SGA quetiapine and the tricyclic antidepressants amitriptyl-
ine and imipramine, have been linked to myocarditis, and
they are all chemically related to clozapine. Second, while
the patient had used the other medicines for several
months/years, olanzapine was introduced 8 weeks before
the time of death. Noteworthy, clozapine-induced EM most
often becomes clinically relevant after 2 to 4 weeks of treat-
ment [13]. And third, animal studies indicate that several
antipsychotics can cause various cardiac abnormalities
reminiscent of myocarditis, suggesting that there might be
a class effect (Belhani et al. [11]).
Toxicological analyses of blood from case 2 revealed
presence of aripiprazole, olanzapine and mirtazapine. Im-
portantly, the concentration of aripiprazole was signifi-
cantly elevated. While this patient had taken olanzapine
for almost 4 years, treatment with aripiprazole and mirta-
zapine was initiated about 6 months prior to the time of
death. Based on this information, it is tempting to suggest
that EM was induced by aripiprazole in this patient. How-
ever, a contributing role by olanzapine is still a possibility,
either on its own or in combination with aripiprazole.
Noteworthy, histological examination of the heart revealed
several areas with fibrosis and myocyte necrosis. Since
these lesions were of different age, there is a possibility
that some of them were more than 6 months old, e.g. from
the period when the patient was treated with olanzapine
as monotherapy. The subsequent introduction of aripipra-
zole may then have worsened the condition, for instance
as a consequence of the class effect of antipsychotics
described above. Furthermore, an involvement of mirtaza-
pine can not be excluded, although it has never been
linked to myocarditis in the past.
Olanzapine-induced EM may be less common because
of lower therapeutic dosage than clozapine. Although not
confirmed by solid evidence, inventories have suggested
that drug hypersensitivity reactions may be more common
in less potent drugs, i.e. therapeutic dosages >100 mg/day,
most likely because of higher production of reactive me-
tabolites [14]. In both cases, olanzapine was used at higher
dosages than recommended (20 mg as stated in the sum-
mary of product characteristics), which may have contrib-
uted to the development of EM. Lower production of
reactive metabolites with more potent drugs, i.e.
olanzapine, may warrant longer time to achieve sufficient
levels of reactive metabolites. This is also supported by the
fact that EM developed later than the usual 2–4 weeks
observed with clozapine.
In general, when drug-induced EM is diagnosed, the
offending drug should be removed immediately. In critic-
ally ill patients with cardiac failure, hemodynamic stability
must be ensured using the proper means. Otherwise,
standard medical treatment for cardiac failure should be
given. Treatment with immunosupressants is warranted,
usually corticosteroids, but other agents have also been
used successfully (e.g. azathioprine, mycophenolate) [1].
The data presented in this paper should be interpreted
within their limitations, e.g. both patients were prescribed
other medications and our limited information about the
two fatal cases.
Conclusion
Here, we report a possible association between olanzapine
and EM. However, there is a paucity in well-controlled
molecular, cellular and whole-system experiments estab-
lishing a causal explanation. More studies are clearly
warranted to elaborate on this topic. In the mean time
psychiatrists should be aware of myocarditis when patients
developing fever and flu-like symptoms.
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